Bionik Laboratories Corp. (OTCQX: BNKL) is engaged as a medical device and robotics company. Shares of the medical company are gaining 11.25%, through early trading on Tuesday, March 7, 2017. Over the past three months, Bionik Laboratories Corp. has seen average daily volume of 3,940 shares. However, volume of 186,848 shares or dollar volume of $127,635, has already exchanged hands Tuesday.
Shares of Bionik Laboratories Corp. is gaining on Tuesday, after the company announced that it has named Bill Harris as the new Marketing Director. Harris has 20 years of experience in strategic marketing, product management, and engineering. Here is the full press release detailing of the newly appointed marketing executive:
Bionik Laboratories Corp. Press Release:
TORONTO and BOSTON, March 07, 2017 (GLOBE NEWSWIRE) — Bionik Laboratories Corp. (BNKL) (“Bionik” or the “Company”), a global pioneer in evidence based rehabilitation and assistive robotic solutions from hospital to home for people with mobility challenges, announced today that it has appointed Mr. Bill Harris as the company’s Marketing Director.
“Management is extremely pleased with the addition of Bill and the direction of our commercial sales and marketing operations,” stated Mr. Peter Bloch, Chief Executive Officer and Chairman of the Board. “Bionik has an extensive portfolio of industry-leading rehabilitation robots in the market currently. We are committed to commercializing additional products on a large scale. This strategic hire will allow us to aggressively market all our products to new customers across the continuum of care.”
Mr. Harris brings more than 20 years of strategic marketing, product management and engineering experience to his role as marketing director at Bionik. With a diverse technical and business skill set, he will be responsible for implementing the brand strategy and promise, as well as guiding product line development of the Bionik robots. He has a proven track record of success having previously developed and executed the marketing strategy for the OLYMPUS ENDOEYE FLEX 3D, garnering eight industry awards including the 2013 Edison Award for Surgical Aids and; the 2014 ATA Award for Breakthrough Technology of the Year.
Mr. Harris commented, “I am extremely pleased to join Bionik as we continue to add to the more than 240 hospitals in which our robotic products are currently utilized. In addition to three commercially available robots, we have four more exciting products in development. I am looking forward to being a part of the Bionik team as we address the rapidly growing human need for our evidenced based rehabilitation and mobility solutions.”
About Bionik Laboratories Corp.
Bionik Laboratories (BNKL) is a global, pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impaired patients, including three products on the market and four products in varying stages of development. The InMotion Systems – the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist.
For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn and Facebook.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.